Tenalisib
- Generic Name
- Tenalisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H18FN5O2
- CAS Number
- 1639417-53-0
- Unique Ingredient Identifier
- 2261HH611H
- Background
Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib (RP6530)).
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Rhizen Pharmaceuticals SA
- Target Recruit Count
- 40
- Registration Number
- NCT06189209
- Locations
- ๐ฎ๐ณ
Meenakshi Mission Hospital & Research Center, Madurai, Tamil Nadu, India
๐ฎ๐ณMumbai Oncocare Centre, Mumbai, Maharashtra, India
๐ฎ๐ณSahyadri Super Speciality Hospital, Pune, Maharashtra, India
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Rhizen Pharmaceuticals SA
- Registration Number
- NCT05239910
- Locations
- ๐บ๐ธ
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Rhizen Pharmaceuticals SA
- Target Recruit Count
- 21
- Registration Number
- NCT04204057
- Locations
- ๐ต๐ฑ
Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J., Chorzow, Poland
๐ง๐ฌUniversity Multiprofile Hospital for Active Treatment "Sv Ivan Rilski" Ltd, Sofia, Bulgaria
๐ง๐ฌUniversity Multiprofile Hospital for Active Treatment "Dr Georgi Stranski" Ltd.,, Pleven, Bulgaria
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Rhizen Pharmaceuticals SA
- Target Recruit Count
- 33
- Registration Number
- NCT03770000
- Locations
- ๐บ๐ธ
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธUniversity of Colorado Cancer Center, Aurora, Colorado, United States
๐บ๐ธRush University Cancer Center, Chicago, Illinois, United States
Compassionate Use Study of Tenalisib (RP6530)
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Rhizen Pharmaceuticals SA
- Target Recruit Count
- 17
- Registration Number
- NCT03711604
- Locations
- ๐บ๐ธ
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
๐ฌ๐ชLtd. M.Zodelava Hematology Centre, Tbilisi, Georgia
๐บ๐ธDivision of Hematology, University of Colorado,, Denver, Colorado, United States
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
- Conditions
- Interventions
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- Rhizen Pharmaceuticals SA
- Target Recruit Count
- 2
- Registration Number
- NCT03471351
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
๐บ๐ธUniversity of Washington, Seattle, Washington, United States
๐บ๐ธRhizen Pharmaceuticals investigational trial site; Karmanos Cancer Institute,, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.